Galenika's privatisation is suspended in Serbia
This article was originally published in Scrip
Serbia's national privatisation agency has announced that it is no longer selling its 70% stake in Galenika, the country's largest pharmaceutical manufacturer, and that no tenders will be organised this year. It said that no bidders could meet the requirements it had outlined.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.